|
|
| Neurologie > Etude de marché sectorielle |
| Pipeline Insight: Migraine - Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries |
|
|
|
|
€ 9 120,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Décembre 2006 |
Taille du document : |
234 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (2) |
|
|
|
| 21 pages | Octobre 2006 | Anglais
|
|
|
| Main
focus: |
clinical trial,pharmaceutical,clinical trials,...,...
|
| Research
focus: |
market size and estimates,economy outlook |
| Geographic
focus: |
china,japan,india,indonesia,malaysia,singapore,... |
| |
|
|
|
|
| 21 pages | Septembre 2006 | Anglais
|
|
|
| Main
focus: |
clinical trial,clinical trials,toxicology,...
|
| Research
focus: |
market outlook,market size and estimates, |
| Geographic
focus: |
usa,canada,spain |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
MarketWatch: CNS
29 pages | Mars 2005 |
Datamonitor's CNS MarketWatch is a one-stop news shop for timepressed executives.
It provides monthly insight into the key events in the CNS industry.
The report contains the latest news, analys |
160,00 €
|
| |
| |
MarketWatch: CNS
23 pages | Mars 2006 |
Datamonitor's CNS MarketWatch is a one-stop news shop for timepressed executives.
It provides monthly insight into the key events in the CNS industry.
The report contains the latest news, analys |
170,00 €
|
| |
| |
World Alzheimer’s Drugs Market, 2005-2011
1 pages | Mai 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
05-070: The Neuroscience Perspective: Opportunities for Market Entry & Expansion
138 pages | Octobre 2005 |
This report provides suppliers with critical information regarding neuroscientists’ preferred techniques and instrumentation in four strategic areas: nucleic acids, proteins, cells and imaging |
2 400,00 €
|
| |
| |
New Drugs in Development for Anxiety
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
The World Sleep Disorders Market, 2005-2010
87 pages | Septembre 2005 |
The sleep disorder treatment market had sales of $2.03bn in 2004.
It is dominated by one product, Ambien indicated for the short-term treatment of insomnia and providing Sanofi-Aventis with an 87% |
2 219,00 €
|
| |
| |
Zoloft Annual Sales, 2000-2006
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
MarketWatch: CNS
27 pages | Mai 2005 |
Datamonitor's CNS MarketWatch is a one-stop news shop for timepressed executives.
It provides monthly insight into the key events in the CNS industry.
The report contains the latest news, analys |
160,00 €
|
| |
| |
Drugs in Development for Neurological Disorders, 2003
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
MarketWatch: CNS
25 pages | Janvier 2005 |
Datamonitor's CNS MarketWatch is a one-stop news shop for timepressed executives.
It provides monthly insight into the key events in the CNS industry.
The report contains the latest news, analys |
160,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Pipeline Insight: Migraine - Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries |
|
|
Introduction
After the launch of Trexima in 2007, triptan genericization coupled with a weak late-stage pipeline will result in a major shift in market dynamics, and will result in the migraine market value decreasing to $3.2 billion in 2015. The market remains receptive to superior prophylactics however, with innovation being essential for the progression of the acute market, post-triptan era.
Scope
Analysis of patient potential, unmet needs and clinical trial design in migraine
Overview of drugs in preregistration, Phase III, II and I; with analysis of key companies involved in the R&D pipeline
Detailed profiles of key compounds in development for use in migraine, with forecasts of drug revenues to 2015
Discussion of GSK and Pozen's strategies and insight from key industry opinion leaders
Highlights
Due to Imitrex's commercial success, GSK is the current migraine market leader. Trexima, co-developed by GSK and Pozen represents GSK's product line extension for its migraine franchise, but approval delays and the impending US sumatriptan patent expiry will limit its success.
The next big thing in the prophylactic market will be the label expansion of Allergan's Botox and Ipsen's Dysport. Seven major market Botox and Dysport combined sales for migraine are forecast to grow to over $170m in 2015.
The presence of glutamatergic receptor inhibitors, NOS inhibitors and CGRP antagonists, amongst others in early stage clinical trials, indicate companies are developing innovative drugs for the post triptan future. With all identified to play a role in the biological mechanisms of migraine, there holds great potential in such novel drug targets.
Reasons to Purchase
Understand unmet needs in the migraine market based on key opinion leader comments
Benchmark key late-stage migraine compounds against current market leaders
Assess the combined US, Japan, five major EU sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential
|
|
Pipeline Insight: Migraine - Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries
|
|
|
PPLSEN
|
|
|
|
|
